- Round led by PXN Ventures, with additional funding from existing investors IQ Capital and Northern Gritstone
- Company uses quantum physics, AI modelling and deeply integrated laboratory automation and robotics in a closed loop system to engineer enzymes, transforming their performance for industries including pharmaceutical manufacturing, personal care and sustainable chemical production
- Work with a Fortune 500 personal care company delivering over 670x improvements in enzyme performance
- Guy Levy-Yurista joins as CEO to spearhead growth in closed loop AI-guided enzyme engineering
Manchester, UK, 21 May 2026: Imperagen, a Manchester-based techbio company using AI and quantum physics to engineer better enzymes faster, has closed a £5 million seed funding round led by PXN Ventures with participation from Imperagen’s existing investors IQ Capital and Northern Gritstone.
The raise brings Imperagen’s total funding to £8.5 million and will accelerate research and development, expand its wet lab capabilities, and build out its go-to-market function over the next 18 months.
Coinciding with the round Guy Levy-Yurista, PhD joins as CEO. An experienced technology and life sciences executive with two successful exits across the US and Europe, he brings a track record of scaling deep tech businesses from early stage to market leadership.
Enzymes are biological catalysts used to reduce waste, lower energy usage and decrease overall production costs in everything from pharmaceutical manufacturing and personal care to sustainable chemical production. However, engineering an enzyme for practical application is a challenging and complex process. Traditional approaches rely on manual screening, a slow and expensive process with a low hit rate. More recently, zero-shot methods have promised smart designs but often fall short when deployed in real world conditions. Neither method gives industrial customers the predictability and speed they need to de-risk product development at scale.
Imperagen’s proprietary platform combines three stages into a single closed-loop system:
- Quantum physics simulates millions of mutation combinations in silico, generating a rich dataset of predicted properties.
- Those outputs are used to train problem-specific AI models, not general-purpose ones, calibrated to the precise engineering challenge at hand.
- Automated robotics then test the highest-performing predictions in the physical lab, producing high-quality experimental data that feeds directly back into the AI model, so that it continuously evolves.
That feedback loop is what sets the approach apart, with each round of experiments making the next round more targeted. The system learns from the wet lab as it goes, narrowing in on the highest-performing variants with each iteration. The result is a platform that gets smarter round by round. This is the future of biocatalysis, a recursive, self improving AI platform to help rewrite chemical reactions.
The company has already worked on a number of significant projects, including with a Fortune 500 personal care company looking to launch a new product line. Imperagen’s AI-guided closed loop system improved the productivity of two enzymes by 677x and 572x respectively in just five rounds.
Commenting on the news, Dr. Levy-Yurista said: “What I see right now is that the companies that will make a radical difference in this emerging AI-driven future are all AI-native, lean on real world data, have genuine impact, and are fundamentally deep tech. Imperagen has each of those characteristics, combining them with outstanding people, phenomenal technology and the undeniable swagger you only get from Manchester. It was a no-brainer to join the team and lead this next stage in its growth.”
The funds will be used to accelerate the core R&D platform, scale the wet lab operation, and grow the in-house AI team, both human and agentic. Imperagen will also invest in its go-to-market function to convert growing commercial interest into contracted revenue across its target sectors: pharmaceuticals, life sciences, personal care, sustainable fine chemicals, and industrial biotech.
PXN invested via the GMC Life Sciences Fund By PXN Ventures, which it manages on behalf of the Bruntwood SciTech, Enterprise Cheshire + Warrington and Greater Manchester Combined Authority. Investment has also come from NPIF II – PXN Equity Finance, which is managed by PXN as part of the Northern Powerhouse Investment Fund II (NPIF II).
Sim Singh-Landa, Investment Director at PXN, said: “The North West’s life sciences ecosystem is becoming stronger all the time and stands to gain from Imperagen’s local hiring and growth plans, building on the company’s connection to the University of Manchester’s Manchester Institute of Biotechnology. We’re excited to be supporting Imperagen with investment from both the GMC Life Sciences Fund and the Northern Powerhouse Investment Fund II as the company looks to scale success in enzyme engineering and deliver progress within the life sciences sector, which is one of the key sectors highlighted in the UK Government’s Modern Industrial Strategy.”
Imperagen was founded in November 2021 by Dr. Andrew Almond, Dr. Andrew Currin and Dr. Tim Eyes, all researchers from the University of Manchester’s Manchester Institute of Biotechnology.
-ENDS-
Notes to editors
For more information, please contact imperagen@yourstorypr.com.
About Imperagen
Established in 2021 by researchers from the Manchester Institute of Biotechnology, Imperagen is a pioneering techbio company, focused on accelerating the process of enzyme engineering. Serving diverse markets, from pharmaceutical manufacturing and life sciences to sustainable fine chemical production and industrial applications, we work hand-in-hand with our customers to de-risk and streamline their product development and fast track their path to market. We’ve raised £8.5 million, and our investors include PXN, IQ Capital and Northern Gritstone.
About the GMC Life Sciences Fund by PXN Ventures
The GMC Life Sciences Fund by PXN Ventures is a £20m investment fund by Greater Manchester Combined Authority, Enterprise Cheshire and Warrington, Bruntwood SciTech and PXN Ventures. The fund was launched in May 2022 by the Mayor of Greater Manchester Andy Burnham and supports life sciences businesses based in the region or those who are committed to scaling here.
About the Northern Powerhouse Investment Fund II
The £660m Northern Powerhouse Investment Fund II (NPIFII) covers the entire North of England and provides loans from £25k to £2m and equity investment up to £5m to help a range of small and medium sized businesses to start up, scale up or stay ahead.
The purpose of the Northern Powerhouse Investment Fund II is to drive sustainable economic growth by supporting innovation and creating local opportunity for new and growing businesses across the North of England. The Northern Powerhouse Investment Fund II will increase the supply and diversity of early-stage finance for the North’s smaller businesses, providing funds to firms that might otherwise not receive investment and help to break down barriers in access to finance.
- Operated by the British Business Bank, the Northern Powerhouse Investment Fund II (NPIF II) provides a mix of debt and equity funding. NPIF II will offer a range of commercial finance options with smaller loans from £25k to £100k, debt finance from £100k to £2m and equity investment up to £5 million. It works alongside the Combined Authorities, Local Enterprise Partnerships (LEPs), and Growth Hubs, as well as local intermediaries such as accountants, fund managers and banks, to support the North’s smaller businesses at all stages of their development.
- The funds in which the NPIF II invests are open to businesses with material operations, or planning to open material operations, in: Cheshire, Cumbria, Greater Manchester, Lancashire, Merseyside, City of Kingston upon Hull, East Riding of Yorkshire, North Yorkshire, South Yorkshire, West Yorkshire, Hartlepool and Stockton-on-Tees, South Teesside, Darlington, Durham, Northumberland, Tyneside, Sunderland.
Smaller Loans from £25,000 to £100,000 – GC Business Finance & River Capital (North West), Business Enterprise Fund (BEF)(Yorkshire and Humber) and NEL Fund Managers (North East)
Business Loans from £100,000 to £2m – FW Capital (North West), Mercia (Yorkshire and Humber) and NEL Fund Managers(North East)
Equity Finance up to £5m – PXN Ventures (North West), Mercia (Yorkshire and Humber), and Maven Capital Partners (North East)
Applications for funding are made directly to the relevant fund managers who can be contacted via the NPIF II webpages www.northernpowerhouseinvestmentfund.co.uk
About PXN Ventures
PXN Ventures is the venture capital arm of PXN Group, formed following the merger of Praetura Ventures and Par Equity. With offices in Manchester, Edinburgh, Leeds and London, we deliver world-class investment programmes at scale to help build the Northern economy, supporting founders across a diverse range of sectors, including deep tech, life sciences and software. PXN Ventures is committed to backing early-stage founders across the North of the UK, with a long and growing list of northern success stories such as Modern Milkman, Phlo, AccessPay, Street Group and Advanced Electric Machines.
The post University of Manchester techbio spin-out secures £5 million to deploy quantum physics, AI modelling, and highly automated labs to power next gen enzyme engineering appeared first on World Bio Market Insights.
